aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Avenge Bio was founded by an experienced team of biotech executives with the core mission of developing transformative therapeutics aimed at eradicating intractable solid tumors. The company focuses on creating cell-generated immunotherapies using their proprietary allogeneic LOCOcyte™ platform, which enables the precision delivery of cytokines and other potent immunomodulatory molecules for controlled periods. Avenge Bio's market focus is on providing innovative solutions for cancer treatment, particularly targeting solid tumors that are difficult to treat with existing therapies.
Notable affiliated individuals and investors include seasoned biotech professionals with a track record of success in the industry. Avenge Bio has achieved significant milestones in the development of its LOCOcyte™ platform, demonstrating promising preclinical results. The company's impact lies in its potential to revolutionize cancer treatment by offering new therapeutic options that could significantly improve patient outcomes in cases of solid tumors.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Immunotherapies
Technology
Biotech
Tags
Healthtech
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Avenge Bio founded?
Avenge Bio was founded in 2019.
Where is Avenge Bio's headquarters located?
Avenge Bio's headquarters is located in Cambridge, MA, US.
When was Avenge Bio's last funding round?
Avenge Bio's most recent funding round was for $45M (USD) in January 2022.
How many employees does Avenge Bio have?
Avenge Bio has 23 employees as of Feb 4, 2024.
How much has Avenge Bio raised to-date?
As of July 05, 2023, Avenge Bio has raised a total of $45M (USD) since Jan 5, 2022.
Add Comparison
Total Raised to Date
$45M
USD
Last Update Jan 5, 2022
Last Deal Details
$45M
USD
Jan 5, 2022
Series A
Total Employees Over Time
23
As of Feb 2024
Avenge Bio Address
Cambridge,
Massachusetts
02138
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts